3 ms·
I'd say this paper forms the basis for pre-clinical trials. First in-vitro with cell cultures, then in model organisms... So maybe a few years until first Huma
by bayesian_horse 5y ago
I'd say this paper forms the basis for pre-clinical trials. First in-vitro with cell cultures, then in model organisms...
So maybe a few years until first Human trials if they are fast? Maybe up to a decade for full approval? As to the chance nobody can say. Too many factors go into that.
- dekhn 5y agothere isn't data in this paper to support going to human clinical trials. micromolar inhibitors are a starting point for further molecular development, not invivo cell work.
- bayesian_horse 5y agoI didn't say anything else... I was sketching the path this research has to go for the benefit of a lay reader, provided nothing show-stopping occurs. The small molecule they propose may actually go all the way to Human trials, even though there is a high probability it will not turn out to do something useful. They already used it on some kind of CDK20 activity assay. Maybe they modify it somewhat, but the next step would be to find out what it does in some kind of cell culture? I'm not an expert in drug development or this specific cancer.